Clinical Use of Prazosin in CHF
To the Editor: I read with great enthusiasm the work of Dr. Dean T. Mason (Circulation 56: 346, 1977 ) on administration of prazosin to patients with congestive failure.
In sheer clinical despair we began chronic use of prazosin approximately a year ago in several class IV congestive failure patients. Of fourteen patients in our group, three have been on prazosin for nearly a year. All have noted marked clinical improvement in functional class, and most have experienced a lessening of the need for large amounts of diuretic therapy, fluid restriction and nitrate administration. One has experienced a reduction in his clinical need for bronchodilator therapy.
The criteria for utilization of prazosin in our office are that the patient should be New York Heart Association class IV functionally; should have been on maximal medical management for congestive failure; should have no cardiac surgical hope short of transplant; should have signed an informed consent form; and finally should be a very compliant patient.
The protocol for our initial visit is that the patient is seen for six hours in the office after administration of 1 mg of prazosin and that pulse and blood pressure are obtained every thirty minutes. During subsequent visits, subjective evaluation of functional class is obtained, a careful physical examination is made with special attention to pulse, blood pressure, weight and state of hydration. At this visit a decision is made regarding liberalization of fluid restriction, possible reduction of diuretic dosage or possible increase in prazosin dosage.
It has been our experience that the initial dosage of 1 mg every twelve hours has been an adequate starting dose for most normal or slightly hypotensive patients and this can be adjusted upward during follow-up therapy. In only one patient, who is hypertensive, were we required to use a total daily aose of 15 mg.
We feel strongly that prazosin will play an important part in management of congestive failure in the future but hope that the changing status of the patient's needs regarding the above variables will not mask the clinical value of this medication. EDWARD J. STRAUB, M.D. 2919 Swann Avenue Tampa, Florida 33609
Systolic Time Intervals
To the Editor: The review of systolic time intervals (STI) by Lewis and colleagues' is a superb analysis of the increasing work in this fruitful field. Two methodologically important aspects of their presentation deserve further elucidation because they are more or less at variance with other findings: 1) paper speed for registration of STI; 2) heart rate correction of pre-ejection period (PEP).
The authors cite the first of our three publications on the relationship of paper speed to precision of pulse wave measurements.2 They state that a reanalysis of data from our paper resulted in support for their finding that 100 mm/sec paper speed is optimal for recording LVET. Their figure 6 indeed shows not only reduced mean observer difference from computer-digitized measurements but also much less observer variability at the 100 mm/sec paper speed in a study of pulse waves from seven patients at three different speeds. Although the authors refer to that earlier work as the "only direct study of the problem" they have over-looked both our report on optimal paper speed in apexcardiog-raphy3 and another publication by us in which ten different subjects were studied at five different paper speeds of 25, 50, 75, 100 and 200 mm/sec.4 This work was a comprehensive study of all individual points of measurement as well as all calculated systolic time intervals (including q-S 1 M and external isovolumic contraction time) and also the pulse transmission time (PTT) and cycle length (R-R). However, I cannot fault the authors for overlooking that publication because, although in some detail, it appears as an extended abstract and the final manuscript is still in preparation. That study was completely coded and randomized to reduce observer bias so that observers could never read data from the same subject in sequence except by chance. It showed no statistically significant differences in overall observer performance for all measurements between paper speeds of 50 and 200 mm/sec. For LVET this was true at all speeds, i.e., 25-200 mm/sec. However, when observer variability was analyzed, observer differences showed closest numerical agreements at 200 and 100 mm/sec with the 100 mm/sec speed being optimal. Yet the differences for the 25 mm/sec speed for LVET (only) were not biologically significant (mean observer difference 1.2 msec) and, in fact, not statistically different. These raise important methodologic considerations and I solicit comments from Dr. Lewis and colleagues including a description of the steps in his study to minimize bias. Specifically, were the observers measuring from completely and individually differently randomized strip charts? If not, sequentially measured data from the same patient could introduce serious bias.
Correction of pre-ejection period for heart rate, "PEPI," has been a needlessly vexed question. Although the authors have, indeed, produced a thoughtful critical review of the STI, this is one aspect which was not critically reviewed. Unlike LVET, which is clearly rate-related both in pooled basal subjects and in individuals during atrial pacing, PEP often has an apparent rate correlation but no true (i.e., direct) relationship. There is now a burgeoning literature which both directly and indirectly indicates that ratecorrection of the PEP is erroneous.5`These reports demonstrate that in pooled resting subjects there is at best a weak to vanishing apparent correlation (r between 0 and -0.4) between PEP and heart rate. Our most recent investigation in pooled normal subjects of the Framingham Heart Study (manuscript in preparation) showed a nonsignificant correlation coefficient for PEP vs heart rate in 281 normal males of less than -0.1; in 410 normal females the correlation coefficient was only -0.116 and was of borderline significance. 794, 1975 The author replies: To the Editor:
We wish to thank Dr. Spodick for his comments on our manuscript. Apparently he is in agreement with our results which indicate 100 mm/sec is the optimum paper speed. He raised the question of observer bias. We indeed conducted our study as he suggested ... "completely coded and randomized to reduce observer bias so that observers could never read data from the same subject in sequence except by chance." All observers received individual copies of each taperecorded pulse arbitrarily coded and in random order according to patients and paper recording speeds.
Apparently in Dr. Spodick's as yet unpublished study, he found no statistically significant difference for the LVET while we noted such a difference. It should be noted that we used a computer analysis to achieve a standard against which to judge the LVET measurements at each paper speed. This may account for our different results. However, even if the mean values were not statistically different, the greater observer variability at slower speeds dictates that 100 mm/sec is the optimal recording speed. I feel that this debate over paper speed has become somewhat academic since modern technology has resulted in a number of different recording devices with 100 mm/sec capability.
The argument over whether to correct the PEP for heart rate is essentially an "empirical vs functional" argument. Until it can be proved that PEP is functionally independent of heart rate, we must rely on carefully collected empirical data. From such studies it is clear that a significant, albeit weak, correlation exists. Naturally, only studies with large numbers of subjects will reveal this relationship. Atrial pacing data cannot be applied to this situation, as this is an unnatural mode of increasing the heart rate (i.e., no 
Small vs Large Surface Area Electrodes
To the Editor:
We were interested in the article by Hughes et al. (Circulation 54: 128, 1976) because the promise of lower long-term thresholds with small-area electrodes has brought them into widespread use. If a hazard exists in their failure to sense, it would seriously jeopardize their use, as competitive pacing is still a highly unattractive and potentially harmful long-term complication.
We would agree with the observations of the authors that the combination of a small-area electrode and a low input impedance of the detection device may lead to failure of sensing. However, we would like to assert that small-area electrodes coupled with high impedance detection circuits such as are used in most modern pacemakers do not constitute such a hazard. In other words, the signal provided by a small-area electrode is determined by the combination of the interface impedance of the electrode and the input impedance of the detection device, or pacemaker. Also, a small-area electrode should produce a larger and sharper inherent signal than a very large area (within limits) since the large area will average the signal more than a smaller one.
The failure to clearly point out the unique and almost artificial circumstances of their experiments is illustrated in their table 1. The results demonstrate how the 1 KU load, in combination with the electrode impedance, attenuates the signal strength. As pointed out by the authors, the 1 KQ load is much lower than commercially available pulse generators. The effects with actual pacemakers having impedances of 20 Kg will be about twenty times less severe. The true "sensed" electrogram would be represented by an unloaded measurement, but these values are unfortunately not provided. Some other points are: 1) bipolar electrodes do not inherently sense smaller signals than unipolar electrodes.
2) Fibrous tissue does not greatly affect the electrode-tissue impedancethe impedance is mainly at the metal-electrolyte interface. The fibrous tissue does, however, separate the electrode from viable tissue and so reduces the sensed signal.
3) In figure 5 , the electrode tip design for optimal sensing is surely offered as an example of principle rather than as an actual electrode. The geometry of the large band sensing electrode is such that it would be very difficult to have it in intimate contact with excitable tissue if used as an endocardial electrode.
In summary, small-area electrodes as they are currently used do not constitute a hazard for sensing when the higher interface impedance associated with these electrodes is appropriately used with a higher input impedance of the detecting pacemaker.
T. E. CUDDY, M.D. M. B. RABER, P.ENG.
University of Manitoba
Winnipeg, Manitoba
The authors reply:
We agree completely with Dr. Cuddy that bipolar electrodes are not inherently inferior to unipolar electrodes. The ability of any type electrode to sense R-wave potentials is based primarily on its surface area, not the mode in which sensing is done.' I hope we did not leave that impression with anyone in our paper.
Secondly, we have only limited information of the chronically implanted electrodes' ability to sense. We would, however, expect the sensing ability to be reduced by fibrous tissue ingrowth.
